BIO-RAD LABORATORIES, INC.
For the period ended Sep 30, 2025. Filed Oct 29, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Oct 29, 2025
BIO-B$389.98+2.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Nine Months Ended | ||
|---|---|---|
| September 30, | ||
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Cash received from customers | $1,958.7 | $1,921.0 |
| Cash paid to suppliers and employees | (1,511.4) | (1,531.3) |
| Interest paid, net | (45.5) | (45.6) |
| Income tax payments, net | (54.3) | (75.7) |
| Dividend proceeds and miscellaneous receipts, net | 62.7 | 67.1 |
| Payments for forward foreign exchange contracts, net | (42.9) | (4.5) |
| Net cash provided by operating activities | 367.3 | 331.0 |
| Cash flows from investing activities: | ||
| Payments for purchases of property, plant and equipment | (111.8) | (122.7) |
| Proceeds from dispositions of property, plant and equipment | 0.1 | 0.1 |
| Payments for acquisitions, net of cash received | (218.5) | — |
| Payments for acquired in-process research and development | — | (23.4) |
| Payments for purchases of marketable securities and investments | (530.5) | (1,053.7) |
| Proceeds from sales of marketable securities and investments | 646.2 | 900.5 |
| Proceeds from maturities of marketable securities and investments | 59.0 | 169.5 |
| Net cash used in investing activities | (155.5) | (129.7) |
| Cash flows from financing activities: | ||
| Payments on long-term debt | (0.3) | (0.4) |
| Payments for debt issuance costs | — | (0.6) |
| Proceeds from issuance of common stock and from reissuance of treasury stock under the employee stock purchase plan and upon exercise of stock options | 11.9 | 15.3 |
| Tax payments from net share settlement | (2.6) | (3.3) |
| Payments for purchases of treasury stock | (295.5) | (203.6) |
| Net cash used in financing activities | (286.5) | (192.6) |
| Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash | (16.9) | (0.9) |
| Net increase (decrease) in cash, cash equivalents and restricted cash | (91.6) | 7.8 |
| Cash, cash equivalents and restricted cash at beginning of period | 489.8 | 404.4 |
| Cash, cash equivalents and restricted cash at end of period | $398.2 | $412.2 |
Reconciliation of cash, cash equivalents and restricted cash (in millions):
| September 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash and cash equivalents | $395.8 | $410.4 |
| Restricted cash included in Other current assets | 2.0 | 1.4 |
| Restricted cash included in Other assets | 0.4 | 0.4 |
| Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows | $398.2 | $412.2 |
These restricted cash items are primarily related to performance guarantees and other restricted deposits.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.